Literature DB >> 457521

Pregnancy-induced pulmonary hypertension in cows susceptible to high mountain disease.

L G Moore, J T Reeves, D H Will, R F Grover.   

Abstract

Observations in several species suggest that pulmonary vascular reactivity may be reduced during pregnancy. We tested this hypothesis in two groups of unanesthetized cows, one "susceptible" and one "resistant" to high mountain or brisket disease. At the altitude of residence (1,524 m), mean pulmonary arterial pressure was elevated during pregnancy by 18% and total pulmonary vascular resistance by 32% in susceptible but not in resistant cows. During acute exposure to simulated altitudes of 2,120--4,550 m, pulmonary arterial pressure was increased by 16% and total pulmonary resistance by 28% during pregnancy in susceptible cows. The pulmonary pressor response to a 5 microgram/kg bolus of prostaglandin FIalpha was not different during pregnancy in either group. Resistant cows hyperventilated while pregnant, raising arterial partial pressure of oxygen (PaO2) by 6 Torr both at 1,524 m and, on the average, by 7 Torr at altitudes of 2,120--4,550 m. Susceptible cows increased their PaO2 less than did the resistant cows during pregnancy. The results indicated that pregnancy was associated with a greater rise in pulmonary arterial pressure and total pulmonary vascular resistance during acute hypoxia and failed to elicit as great a ventilatory response in susceptible than in resistant cows.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 457521     DOI: 10.1152/jappl.1979.46.1.184

Source DB:  PubMed          Journal:  J Appl Physiol Respir Environ Exerc Physiol        ISSN: 0161-7567


  2 in total

1.  Arterial blood sample collection from the newborn calf.

Authors:  R Adams; M D Holland; B Aldridge; F B Garry; K G Odde
Journal:  Vet Res Commun       Date:  1991       Impact factor: 2.459

Review 2.  Hypoxic pulmonary vasoconstriction.

Authors:  J T Sylvester; Larissa A Shimoda; Philip I Aaronson; Jeremy P T Ward
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 46.500

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.